THE RELATİONSHİP BETWEEN BLOOD GAS PARAMETERS OBTAİNED FROM THE CORONARY SİNUS DURİNG THE PROCEDURE AND CRT RESPONSE İN PATİENTS WİTH HEART FAİLURE WHO UNDERWENT CRT IMPLANTATİON

Heart failure (HF) is one of the clinical syndromes with the highest morbidity and mortality rates among cardiovascular diseases. Despite pharmacological treatments, symptoms persist in a significant proportion of patients, and mortality cannot be prevented. Therefore, device-based therapies, particularly cardiac resynchronisation therapy (CRT), have gained an important place in the treatment algorithm.CRT aims to correct mechanical dyssynchrony by enabling simultaneous contraction of the left and right ventricles. It also aims to reduce sudden cardiac death rates with its defibrillator feature. Current guidelines emphasise that CRT provides significant benefits in terms of symptomatic improvement and long-term survival when appropriate patient selection is made. However, not all patients who meet the criteria have benefited equally from CRT. It is difficult to predict in advance which heart failure patients will benefit from CRT.The aim of the study is to analyse blood gas parameters obtained from the coronary sinus during the procedure in cases of symptomatic heart failure with low ejection fraction despite optimal medical treatment and in patients with indications for CRT according to current guidelines. This analysis aims to contribute to the prior identification of patients who may benefit.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Heart Failure Cardiac Resynchronization Therapy Cardiovascular Diseases Coronary Sinus Heart Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Trakya University Faculty of Medicine Hospital

Edirne, 22100, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients diagnosed with heart failure, with an EF <35, and in heart failure stages 2-3-4 despite optimal medical therapy.
Those who agree to participate in the study.
Patients aged 18 years and older.
Patients with a QRS duration of 135 ms or more on ECG.

Exclusion criteria

Patients with EF 35 or higher.
QRS duration on ECG less than 130 milliseconds.
Not receiving the maximum tolerable dose of medication for KY.
Absence of left bundle branch block morphology on ECG.
History of acute myocardial infarction within the last 3 months.
Estimated life expectancy of less than 1 year.
History of cardiac surgery within the last 3 months.
Elective cardiac surgery planned.
Patients scheduled for CRT prior to nodal ablation.
Patients with intracardiac shunts.
Those who refuse to participate in the study.
Chronic lung diseases (COPD, emphysema, bronchitis, etc.). -

Treatment and study plan

coronary sinus blood sampling

Diagnostic Test

Blood gas analysis by drawing blood from the coronary sinus

Primary outcomes

Combined endpoint of hospitalization for heart failure, death, need for IV diuretics, change in ejection fraction, and change in NYHA classification

Time frame: 6 months

Sponsors and collaborators

Lead sponsor

Trakya University

Other

Registry information

Important dates

Study start: 2022
Primary completion: 2024
Study completion: 2026
First posted: Feb 27, 2026
Registry last updated: Feb 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting